topotecan has been researched along with decitabine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Abbruzzese, JL; Anzai, H; Frost, P | 1 |
Avula, R; Bible, KC; Hartmann, LC; Huang, H; Kalli, K; Kaufmann, SH; Lee, YK; Shridhar, V; Smith, DI; Staub, J | 1 |
Karp, J | 1 |
1 review(s) available for topotecan and decitabine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for topotecan and decitabine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Colorectal Neoplasms; Decitabine; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Lethal Dose 50; Methylation; Mice; Mice, Inbred BALB C; Topotecan; Tumor Cells, Cultured | 1992 |
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.
Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Chromosome Mapping; Cisplatin; Cloning, Molecular; Decitabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Molecular Sequence Data; Ovarian Neoplasms; Oximes; Paclitaxel; Piperazines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Topotecan; Transfection; Tumor Cells, Cultured | 2001 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |